SGLT2is, also known as gliflozin, are a class of drugs that lower blood sugar by increasing its excretion in the urine, while GLP-1RAs, such as Ozempic, work by increasing insulin release and sensitivity.
Impaired glucose control in diabetic patients is known to damage blood vessels in the heart and kidneys.
“The rapidly expanding indications for the use of GLP-1 receptor agonists make it important to look at their effects with SGLT2 inhibitors,” according to lead author Brendan Newen, clinical associate professor at the George Institute for Global Health.
The new findings, published in The Lancet Diabetes & Endocrinology, are based on a meta-analysis of 12 large-scale, placebo-controlled trials of SGLT2is, which included 73,238 patients with diabetes, 3,065 of whom were already receiving GLP1-RAs. .
The results showed that SGLT2is reduced the risk of heart attack, stroke or cardiovascular death by 11 percent, independent of GLP1-RAs.
When added to GLP1-RA, there was also a 23 percent reduction in hospitalization for heart failure or cardiovascular death compared with placebo.
Additionally, the SGLT2is drug reduced the risk of developing chronic kidney disease by 33 percent when added to GLP1-RAs and slowed the annual loss in kidney function by nearly 60 percent when added to GLP-1RAs.
Importantly, no new safety concerns were identified when SGLT2is and GLP-1RAs were used in combination, the team said.
Both classes of drugs work independently of each other, the 2 inhibitors against heart failure and chronic kidney disease; The GLP-1 receptor is an agonist against heart attack, stroke and kidney disease, Nuen said.
Impaired glucose control in diabetic patients is known to damage blood vessels in the heart and kidneys.
“The rapidly expanding indications for the use of GLP-1 receptor agonists make it important to look at their effects with SGLT2 inhibitors,” according to lead author Brendan Newen, clinical associate professor at the George Institute for Global Health.
The new findings, published in The Lancet Diabetes & Endocrinology, are based on a meta-analysis of 12 large-scale, placebo-controlled trials of SGLT2is, which included 73,238 patients with diabetes, 3,065 of whom were already receiving GLP1-RAs. .
The results showed that SGLT2is reduced the risk of heart attack, stroke or cardiovascular death by 11 percent, independent of GLP1-RAs.
When added to GLP1-RA, there was also a 23 percent reduction in hospitalization for heart failure or cardiovascular death compared with placebo.
Additionally, the SGLT2is drug reduced the risk of developing chronic kidney disease by 33 percent when added to GLP1-RAs and slowed the annual loss in kidney function by nearly 60 percent when added to GLP-1RAs.
Importantly, no new safety concerns were identified when SGLT2is and GLP-1RAs were used in combination, the team said.
Both classes of drugs work independently of each other, the 2 inhibitors against heart failure and chronic kidney disease; The GLP-1 receptor is an agonist against heart attack, stroke and kidney disease, Nuen said.
